Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
(MedPage Today) -- In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177Lu-PSMA-617 (Pluvicto) to androgen deprivation therapy (ADT) and chemotherapy more than doubled biochemical recurrence-free survival (BRFS), the...
MedPage Today - Radiology
The Mommyhood Life
Health Care News
Los Angeles Times
iCliniq
Forbes Business Blog
The Conversation » Menopause